Cell and gene therapy developers convened in Rome this week for a field-wide outlook conference, but the dominant topic wasn't European regulation. It was the U.S. Food and Drug Administration. Industry participants expressed deep uncertainty about the agency's current trajectory and its impact on their pipeline decisions.
The conference, focused on the European landscape, unexpectedly became a forum for transatlantic regulatory anxiety. Without explicit changes to FDA policy, attendees described a climate of hesitation among developers weighing clinical trial strategies and manufacturing investments. The Rome setting highlighted how U.S. agency moves ripple across the global gene therapy sector.
Sources at the meeting reported that informal conversations repeatedly circled back to recent FDA personnel shifts and their potential to slow review timelines. No specific policy changes or guidance updates were cited, but the overall sentiment was one of caution rather than alarm. The agency has signaled ongoing commitments to rare disease therapies, leaving the gene therapy field parsing its next signals.
The immediate implications for the sector remain unclear. Several mid-sized developers are reportedly reassessing U.S. trial timelines, while larger players maintain their existing plans. The conference served as an early barometer of how FDA perception shapes capital allocation and partnership decisions in gene therapy. "We've seen this movie before," said one attendee, speaking anonymously due to the sensitivity of regulatory discussions. "A period of drift, then a new direction. The question is how long that interregnum lasts."